Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Douglas Ferguson"'
Publikováno v:
Archives of Breast Cancer, Vol 9, Iss 3 (2022)
Background: Phyllodes tumours of the breast are benign, borderline or malignant fibroepithelial lesions. They are uncommon and usually treated with surgical or radiological excision. The association with local recurrence has led to much debate over t
Externí odkaz:
https://doaj.org/article/0197d775d79e48e3b07684b717c674a8
Autor:
Ardeshir Goliaei, Haley A. Woods, Adriana E. Tron, Matthew A. Belmonte, J. Paul Secrist, Douglas Ferguson, Lisa Drew, Adrian J. Fretland, Bree B. Aldridge, Francis D. Gibbons
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 10, Pp 561-570 (2020)
Anticancer efficacy is driven not only by dose but also by frequency and duration of treatment. We describe a multiscale model combining cell cycle, cellular heterogeneity of B‐cell lymphoma 2 family proteins, and pharmacology of AZD5991, a potent
Externí odkaz:
https://doaj.org/article/07ad18bfe7b84642b234c602cec0a6fa
Autor:
Ari Meerson, Yaniv Eliraz, Hila Yehuda, Bridget Knight, Malcolm Crundwell, Douglas Ferguson, Benjamin P. Lee, Lorna W. Harries
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Obesity increases breast cancer (BC) risk in post-menopausal women by mostly unknown molecular mechanisms which may partly be regulated by microRNAs (miRNAs). Methods We isolated RNA from paired benign and malignant biopsies from
Externí odkaz:
https://doaj.org/article/f42bc0bfe938471bbb941b977d56bcea
Autor:
Thomas H.S. Fysh, Douglas Ferguson
Publikováno v:
Surgical Techniques Development, Vol 1, Iss 1, Pp e5-e5 (2011)
Many closed surgical drainage systems are delivered through the abdominal wall with a trochar. Sometimes this manoeuvre requires significant force, potentially compromising control and causing injury, either to the patient or to operating theatre per
Externí odkaz:
https://doaj.org/article/93f301f3900c4477b5cac50595783cae
Autor:
Makin, Douglas Ferguson1 (AUTHOR) doug.makin4@gmail.com, Kotler, Burt P.1 (AUTHOR), Sargunaraj, Franklin1 (AUTHOR)
Publikováno v:
Israel Journal of Ecology & Evolution. 2021, Vol. 67 Issue 3/4, p121-126. 6p.
Autor:
Srinivasan Krishnan, Diane Ramsden, Douglas Ferguson, Simone H. Stahl, Joanne Wang, Dermot F. McGinnity, Niresh Hariparsad
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:562-572
Transporters contribute to renal elimination of drugs; therefore drug disposition can be impacted if transporters are inhibited by comedicant drugs. Regulatory agencies have provided guidelines to assess potential drug-drug interaction (DDI) risk for
Autor:
Simon T. Barry, Elizabeth J. Pease, Kim Maratea, Lucy A. Young, James E. Pilling, Nicola J. Curtis, Shenghua Wen, Maureen Hattersley, Emily Harris, Adina M. Hughes, Larissa S. Carnevalli, Paula Taylor, Douglas Ferguson, Susan Ashton, Nicolas Floc'h
Supplementary Table 1. Mass Spectrometer and UPLC system parameters, Supplementary Table 2. Optimization parameters for mass spectrometry analysis, Supplementary Table 3. Estimated mouse PK model parameter values for AZD2811, Supplementary Table 4. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9cbc531e729c8e44984c7debbf3242
https://doi.org/10.1158/1535-7163.22504665
https://doi.org/10.1158/1535-7163.22504665
Autor:
Simon T. Barry, Elizabeth J. Pease, Kim Maratea, Lucy A. Young, James E. Pilling, Nicola J. Curtis, Shenghua Wen, Maureen Hattersley, Emily Harris, Adina M. Hughes, Larissa S. Carnevalli, Paula Taylor, Douglas Ferguson, Susan Ashton, Nicolas Floc'h
Barasertib (AZD1152), a pro-drug of the highly potent and selective Aurora B kinase inhibitor AZD2811, showed promising clinical activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients administered as a 4-day infusion. To impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12363a7f9cadd28798c9089e15037fee
https://doi.org/10.1158/1535-7163.c.6537822.v1
https://doi.org/10.1158/1535-7163.c.6537822.v1
Autor:
Lisa Drew, Stephen E. Fawell, Michael Zinda, David M. Weinstock, Raphael Koch, Jamal C. Saeh, Wenlin Shao, Clive S. D'Santos, Chandra Sekhar Reddy Chilamakuri, Valar Nila Roamio Franklin, Nancy Su, Petar Pop-Damkov, Maryann San Martin, Steven W. Criscione, Douglas Ferguson, Theresa Proia, Scott Boiko, Justin Cidado
Purpose:Cyclin-dependent kinase 9 (CDK9) is a transcriptional regulator and potential therapeutic target for many cancers. Multiple nonselective CDK9 inhibitors have progressed clinically but were limited by a narrow therapeutic window. This work des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78a2f9d8bc4116c23d641a6d2430c69
https://doi.org/10.1158/1078-0432.c.6528438
https://doi.org/10.1158/1078-0432.c.6528438
Autor:
Lisa Drew, Stephen E. Fawell, Michael Zinda, David M. Weinstock, Raphael Koch, Jamal C. Saeh, Wenlin Shao, Clive S. D'Santos, Chandra Sekhar Reddy Chilamakuri, Valar Nila Roamio Franklin, Nancy Su, Petar Pop-Damkov, Maryann San Martin, Steven W. Criscione, Douglas Ferguson, Theresa Proia, Scott Boiko, Justin Cidado
Material, methods, supplementary references, and list of supplementary tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::452c2d4f2e72a9f64fb946ec7fddeb69
https://doi.org/10.1158/1078-0432.22473192
https://doi.org/10.1158/1078-0432.22473192